Thermo Fisher Scientific Inc. TMO NYSE

Thermo Fisher Scientific Inc. (TMO) generated $7.82B in operating cash flow for fiscal year 2025. After capital expenditures of $1.53B, free cash flow was $6.29B.

Free cash flow margin was 14.1% of revenue. Cash conversion ratio was 1.16x, indicating earnings are backed by cash.

The company returned $636M in dividends and $3B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (61/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (70/100) — Cash conversion ratio was 1.16x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 63/100 with 3/7 criteria passed.